Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CD63 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD63, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD59 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD59, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD58 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD58, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD55 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD55, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD52 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD52, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD48 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD48, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD46 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD46, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD44 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD44, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD40LG Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD40LG, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD40 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD40, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD36 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD36, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD34 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD34, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.